Home > Urology > EAU 2020 > Prostate Cancer & Imaging > Good tolerance of post-RP radiotherapy ± short-term ADT

Good tolerance of post-RP radiotherapy ± short-term ADT

Presented By
Dr Paul Sargos , Institut Bergonié, France
Conference
EAU 2020
Trial
Phase 2, GETUG-AFU 22
Dr Paul Sargos (Institut Bergonié, France) presented the first results of the GETUG-AFU 22 study and won the second prize in the EAU20 Best Abstract Awards Oncology [1]. The multicentre, randomised, phase 2 GETUG-AFU 22 study, compared 6 months of degarelix short-term androgen deprivation therapy (ADT) in combination with radiotherapy and radiotherapy alone as salvage treatment for patients with detectable prostate-specific antigen (PSA) levels after radical prostatectomy (RP). The primary efficacy endpoint was event-free survival, which will be reported later this year. Key secondary endpoints were toxicity (as measured by CTCAE V4.0) and quality of life (QLQ-C30 and QLQ-PR25) results. Dr Sargos presented ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on